Print  |  Close

A Study to Assess Adjuvant Immunotherapy With Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma


Active: Yes
Cancer Type: Melanoma
Unknown Primary
NCT ID: NCT05002569
Trial Phases: Phase III Protocol IDs: CA224-098 (primary)
NCI-2022-02119
2021-001641-13
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: Bristol-Myers Squibb
NCI Full Details: http://clinicaltrials.gov/show/NCT05002569

Summary

The purpose of this study is to assess relatlimab and nivolumab fixed-dose combination (FDC)
versus nivolumab alone in participants with completely resected stage III-IV melanoma.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.